Study protocol: A strategy for deprescribing statins and ezetimibe in primary prevention of cardiovascular disease in patients older than 75 years: health outcomes analysis"
e202206049
Keywords:
Elderly, Primary prevention of cardiovascular disease, Statins, Deprescription, EzetimibeAbstract
BACKGROUND // The benefit-risk balance of statins and ezetimibe as primary prevention of cardiovascular disease is controversial in elderly patients due to the doubts about their effectiveness and certainty about adverse effects. The aim of this paper was to analyze health outcomes of a statin and ezetimibe deprescription strategy in patients aged 75 or older treated with these drugs for primary prevention of cardiovascular disease.
METHODS // An observational ambispective cohort study was made to evaluate health outcomes after the implementation of a strategy for deprescribing statins and ezetimibe in patients aged 75 or older who take these drugs for primary prevention of cardiovascular disease. To avoid the risk of bias due to non-random assignment of patients to different groups, a propensity score will be calculated for each patient using logistic regression. The outcome of interest will be the deprescription or not of statins or ezetimibe. Time to hospital admission or death from any cause and other variables related to health outcomes will be analysed. Groups with and without statin or ezetimibe deprescription will be compared by survival analysis using Cox regression to estimate the hazard ratio.
CONCLUSIONS // It is expected to obtain health outcomes of the strategy of deprescribing statins and ezetimibe in primary prevention in patients aged 75 or older. They will provide information on the advisability of continuing the strategy.
Downloads
References
Instituto Nacional de Estadística. Tasas de mortalidad por causas (lista reducida), sexo y edad 2018. Consultado 12 de Febrero 2022. Disponible en: https://www.ine.es/jaxi/Datos.htm?path=/t15/p417/a2018/l0/&file=01004.px#!tabs-tabla
Royo-Bordonada MÁ, Armario P, Lobos Bejarano JM et al. Adaptación española de las guías europeas de 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. Gac Sanit. 2017;31:255-268.
Mortensen MB, Falk E. Primary Prevention With Statins in the Elderly. J Am Coll Cardiol. 2018;71:85–94.
Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360:1623–1630.
Giral P, Neumann A, Weill A et al. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: A nationwide population-based cohort study in France. Eur Heart J. 2019;40:3516–3525.
Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 PART B):2889–2934.
Gencer B, Marston NA, Im KA et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396:1637–1643.
Armitage J, Baigent C, Barnes E et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–415.
Cardiovascular disease: risk assessment and reduction, including lipid modification. London: National Institute for Health and Care Excellence (UK); 2016. NICE Clinical Guidelines, No. 181.
Visseren FLJ, Mach F, Smulders YM et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42: 3227-3237.
Subdirección General de Información Sanitaria. Indicadores clínicos en atención primaria: Factores de riesgo y enfermedad cardiovascular. 2016. BDCAP. Madrid: Ministerio de Sanidad, Consumo y Bienestar Social; 2019.
Grupo de trabajo de la semFYC para el proyecto Recomendaciones «NO HACER». Recomendaciones NO HACER. Barcelona: Sociedad Española de Medicina de Familia y Comunitaria; 2014.
Servicio de Investigación, Innovación y Formación Sanitaria. Plan de Salud de Navarra 2014-2020. Pamplona: Departamento de Salud; 2015.
Estrategia de Seguridad del Paciente del Sistema Nacional de Salud. Período 2015-2020. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2016.
Rea F, Biffi A, Ronco R et al. Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy. JAMA Netw Open. 2021: 1; 4 :e2113186.
A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE) (NCT02099123). Consultado 23 de mayo de 2022. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02099123
Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34:3478–3490.
Ali S, Dave N, Virani SS et al. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. Curr Atheroscler Rep. 2019;21:1–9.
Cosentino F, Grant PJ, Aboyans V et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
Nou E, Lo J, Hadigan C et al. Pathophysiology and Management of Cardiovascular Disease in HIV-Infected Patients Eric. Lancet Diabetes Endocrinol. 2017;4:598–610
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Natalia Alzueta Istúriz, Julen Fernández González, Amaya Echeverría Gorriti, Patricia García González, Lorea Sanz Álvarez, Mª Concepción Celaya Lecea, Oihane Goñi Zamarbide, Mª Teresa Acín Gericó, Rafael Bartolomé Resano, Javier Garjón Parra
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
